Efficacy and harms of long‐term opioid therapy in chronic non‐cancer pain: Systematic review and meta‐analysis of open‐label extension trials with a study duration ≥26 weeks
暂无分享,去创建一个
[1] N. Seitz,et al. Trends In Substance Use And Related Disorders. , 2019, Deutsches Arzteblatt international.
[2] Hyon K. Choi,et al. Association of Tramadol With All-Cause Mortality Among Patients With Osteoarthritis , 2019, JAMA.
[3] N. Seitz,et al. Estimation of the Number of People With Opioid Addiction in Germany. , 2019, Deutsches Arzteblatt international.
[4] N. Volkow,et al. Prevention and Treatment of Opioid Misuse and Addiction: A Review , 2019, JAMA psychiatry.
[5] M. Kawamata,et al. Efficacy and safety of controlled-release oxycodone for the management of moderate-to-severe chronic low back pain in Japan: results of an enriched enrollment randomized withdrawal study followed by an open-label extension study , 2019, Journal of pain research.
[6] H. Sadeghi-Nejad,et al. Management Strategies in Opioid Abuse and Sexual Dysfunction: A Review of Opioid-Induced Androgen Deficiency. , 2018, Sexual medicine reviews.
[7] A. Eschalier,et al. Prescription opioid analgesic use in France: Trends and impact on morbidity–mortality , 2018, European journal of pain.
[8] Hongyi Xu,et al. Social commerce: A systematic review and data synthesis , 2018, Electron. Commer. Res. Appl..
[9] S. Marshall,et al. Methodologic limitations of prescription opioid safety research and recommendations for improving the evidence base , 2018, Pharmacoepidemiology and drug safety.
[10] Nabarun Dasgupta,et al. Opioid Crisis: No Easy Fix to Its Social and Economic Determinants. , 2018, American journal of public health.
[11] Mark Edmund Rose,et al. Are Prescription Opioids Driving the Opioid Crisis? Assumptions vs Facts , 2017, Pain medicine.
[12] F. Chung,et al. Opioids, respiratory depression, and sleep-disordered breathing. , 2017, Best practice & research. Clinical anaesthesiology.
[13] Joseph W. Frank,et al. Guideline for opioid therapy and chronic noncancer pain , 2017, Canadian Medical Association Journal.
[14] A. Furlan,et al. The opioid epidemic and national guidelines for opioid therapy for chronic noncancer pain: a perspective from different continents , 2017, Pain reports.
[15] R. Deyo,et al. Comparison of Opioid Prescribing Patterns in the United States and Japan: Primary Care Physicians' Attitudes and Perceptions , 2017, The Journal of the American Board of Family Medicine.
[16] K. Slavin,et al. Responsible, Safe, and Effective Prescription of Opioids for Chronic Non-Cancer Pain: American Society of Interventional Pain Physicians (ASIPP) Guidelines. , 2017, Pain physician.
[17] R. Rauck,et al. Long-term safety and analgesic efficacy of buprenorphine buccal film in patients with moderate-to-severe chronic pain requiring around-the-clock opioids , 2017, Journal of pain research.
[18] J. Pérez-Cajaraville,et al. European Pain Federation position paper on appropriate opioid use in chronic pain management , 2016, European journal of pain.
[19] K. Murray,et al. Prescription of Long-Acting Opioids and Mortality in Patients With Chronic Noncancer Pain. , 2016, JAMA.
[20] R. Chou,et al. CDC Guideline for Prescribing Opioids for Chronic Pain--United States, 2016. , 2016, JAMA.
[21] P. Vergne-Salle,et al. [Use of strong opioids in chronic non-cancer pain in adults. Evidence-based recommendations from the French Society for the Study and Treatment of Pain]. , 2016, Presse medicale.
[22] R. Chou,et al. CDC Guideline for Prescribing Opioids for Chronic Pain - United States, 2016. , 2016, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.
[23] Stephen A. Rappaport,et al. Long-term Safety and Efficacy of Tapentadol Extended Release Following up to 2 Years of Treatment in Patients With Moderate to Severe, Chronic Pain: Results of an Open-label Extension Trial. , 2015, Clinical therapeutics.
[24] Yuju Ma,et al. Twelve-month, open-label assessment of long-term safety and abuse potential of hydrocodone extended-release formulated with abuse-deterrence technology in patients with chronic pain. , 2015, Journal of opioid management.
[25] C. Maier,et al. Erratum zu: Langzeittherapie mit Opioiden bei chronischem nicht-tumorbedingtem Schmerz , 2015, Der Schmerz.
[26] K. Vowles,et al. Rates of opioid misuse, abuse, and addiction in chronic pain: a systematic review and data synthesis , 2015, Pain.
[27] R. Chou,et al. The Effectiveness and Risks of Long-Term Opioid Therapy for Chronic Pain: A Systematic Review for a National Institutes of Health Pathways to Prevention Workshop , 2015, Annals of Internal Medicine.
[28] L. Radbruch,et al. [Recommendations of the updated LONTS guidelines. Long-term opioid therapy for chronic noncancer pain]. , 2015, Schmerz.
[29] C. Sommer,et al. Opioide bei chronischem Kreuzschmerz , 2015, Der Schmerz.
[30] F. Petzke,et al. Opioide bei chronischem Arthroseschmerz , 2015, Der Schmerz.
[31] F. Petzke,et al. Opioide bei chronischem neuropathischem Schmerz , 2014, Der Schmerz.
[32] M. Hopp,et al. Long-term evaluation of combined prolonged-release oxycodone and naloxone in patients with moderate-to-severe chronic pain: pooled analysis of extension phases of two Phase III trials , 2014, Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society.
[33] R. Dworkin,et al. Abuse liability measures for use in analgesic clinical trials in patients with pain: IMMPACT recommendations , 2013, PAIN®.
[34] G. Guyatt,et al. Assessing and presenting summaries of evidence in Cochrane Reviews , 2013, Systematic Reviews.
[35] I. Sutton,et al. Controlled-release oxycodone and naloxone in the treatment of chronic low back pain: a placebo-controlled, randomized study. , 2013, Pain research & management.
[36] R. Sabatowski,et al. Sustained Safety and Efficacy of Once‐Daily Hydromorphone Extended‐Release (OROS® hydromorphone ER) Compared with Twice‐Daily Oxycodone Controlled‐Release Over 52 Weeks in Patients with Moderate to Severe Chronic Noncancer Pain , 2013, Pain practice : the official journal of World Institute of Pain.
[37] J. Ballantyne,et al. Opioid Dependence vs Addiction: A Distinction Without a Difference? , 2012, Archives of internal medicine.
[38] Joseph A Boscarino,et al. Risk factors for drug dependence among out-patients on opioid therapy in a large US health-care system. , 2010, Addiction.
[39] C. Eccleston,et al. “Evidence” in chronic pain – establishing best practice in the reporting of systematic reviews , 2010, PAIN.
[40] A. Sandner-Kiesling,et al. Long-term efficacy and safety of combined prolonged-release oxycodone and naloxone in the management of non-cancer chronic pain , 2010, International journal of clinical practice.
[41] S. Rashiq,et al. Buprenorphine transdermal system in adults with chronic low back pain: a randomized, double-blind, placebo-controlled crossover study, followed by an open-label extension phase. , 2010, Clinical therapeutics.
[42] S. Tregear,et al. Long-term opioid management for chronic noncancer pain. , 2010, The Cochrane database of systematic reviews.
[43] D. Moher,et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement , 2009, BMJ : British Medical Journal.
[44] C. Rutter,et al. De Facto Long-term Opioid Therapy for Noncancer Pain , 2008, The Clinical journal of pain.
[45] C. Thorne,et al. A randomized, double-blind, crossover comparison of the efficacy and safety of oral controlled-release tramadol and placebo in patients with painful osteoarthritis. , 2008, Pain research & management.
[46] J. Farrar,et al. Long-term Use of Controlled-release Oxycodone for Noncancer Pain: Results of a 3-year Registry Study , 2007, The Clinical journal of pain.
[47] M. Zenz,et al. [Long-term efficiency of opioid medication in patients with chronic non-cancer-associated pain. Results of a survey 5 years after onset of medical treatment]. , 2005, Schmerz.
[48] H. Ahdieh,et al. Safety, Tolerability, and Effectiveness of Oxymorphone Extended Release for Moderate to Severe Osteoarthritis Pain: A One-Year Study , 2005, American journal of therapeutics.
[49] J. Hildebrandt,et al. Morphine responsiveness, efficacy and tolerability in patients with chronic non-tumor associated pain – results of a double-blind placebo-controlled trial (MONTAS) , 2002, Pain.
[50] J. Caldwell,et al. Efficacy and safety of a once-daily morphine formulation in chronic, moderate-to-severe osteoarthritis pain: results from a randomized, placebo-controlled, double-blind trial and an open-label extension trial. , 2002, Journal of pain and symptom management.
[51] R. Fleischmann,et al. Around-the-clock, controlled-release oxycodone therapy for osteoarthritis-related pain: placebo-controlled trial and long-term evaluation. , 2000, Archives of internal medicine.
[52] P. Raskin,et al. Maintenance of the long-term effectiveness of tramadol in treatment of the pain of diabetic neuropathy. , 2000, Journal of diabetes and its complications.
[53] G. Smith,et al. Bias in meta-analysis detected by a simple, graphical test , 1997, BMJ.
[54] C. Begg,et al. Operating characteristics of a rank correlation test for publication bias. , 1994, Biometrics.
[55] Robert G. Orwin,et al. A Fail-SafeN for Effect Size in Meta-Analysis , 1983 .
[56] R. Orwin. A fail-safe N for effect size in meta-analysis. , 1983 .
[57] J. O'sullivan,et al. Cushing's syndrome: clinical differential diagnosis and complications. , 1959, Annals of internal medicine.
[58] Innere Medizin. Long-term opioid therapy in chronic noncancer pain A systematic review and meta-analysis of efficacy, tolerability and safety in open-label extension trials with study duration of at least 26 weeks , 2015 .
[59] C. Maier,et al. [Long-term opioid therapy in chronic noncancer pain. A systematic review and meta-analysis of efficacy, tolerability and safety in open-label extension trials with study duration of at least 26 weeks]. , 2015, Schmerz.
[60] Comprehensive Meta‐Analysis Software , 2022, Introduction to Meta‐Analysis.